CN112546284A - Degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing - Google Patents
Degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing Download PDFInfo
- Publication number
- CN112546284A CN112546284A CN202011529855.5A CN202011529855A CN112546284A CN 112546284 A CN112546284 A CN 112546284A CN 202011529855 A CN202011529855 A CN 202011529855A CN 112546284 A CN112546284 A CN 112546284A
- Authority
- CN
- China
- Prior art keywords
- tumor
- photothermal
- degradable
- chemotherapeutic
- synergistic anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/62—Compostable, hydrosoluble or hydrodegradable materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
Abstract
The invention provides a degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing, and belongs to the technical field of biological medicines. The invention firstly utilizes the electrostatic spinning technology to prepare the polylactic acid-glycollic acid fibrous membrane containing the antitumor drug adriamycin; then the prepared composite fiber membrane is immersed in a solution containing dopamine, and a polydopamine layer with a photothermal effect is formed on the surface of the fiber by utilizing dopamine autopolymerization reaction; and finally, cleaning and drying the prepared composite fiber membrane to prepare the degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing. The fiber dressing provided by the invention has the dual anti-tumor effects of photo-thermal and chemotherapy, can thoroughly kill tumor cells of wounds after tumor resection with large area and long effect, can be used for developing novel anti-tumor dressings, and is applied to clinical treatment.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to a degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing.
Background
At present, surgical resection is the main treatment means for early cancer, but the eradication of residual tumor cells after tumor resection is always the key problem of clinical treatment. The traditional dressing takes antibiosis as a main function, and is difficult to meet the application requirement of tumor excision wounds. The research and development of the novel wound dressing with the anti-tumor function are of great significance.
Drug chemotherapy is a main means for treating tumors, however, long-term chemotherapy not only deepens toxic and side effects to patients, but also enables the tumors to generate drug resistance to drugs. Nowadays, the combined tumor therapy of photothermal and chemotherapy is receiving more and more attention. The photothermal method is to irradiate near infrared light to the specific tumor part to produce local high temperature to kill tumor cell without producing medicine resistance. Combining photothermal and chemotherapy allows for more efficient, thorough and durable removal of tumor cells. However, the current photothermal/chemotherapy synergistic anti-tumor technology mostly adopts a method of intravenous injection of drug-loaded photothermal microspheres, which has many limitations, such as low drug loading, great influence by blood circulation instability, aggregation at non-focus sites, excessively fast renal clearance, insufficient uptake of tumor cells, and the like. The development of the in-situ implantable degradable photothermal/chemotherapy synergistic anti-tumor dressing can effectively solve the problems and realize long-acting complete removal of the tumor cells of the wound after tumor resection.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing.
In order to achieve the purpose, the invention adopts the following technical scheme:
a degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing is prepared by the following steps:
step 1, preparing a polylactic acid-glycolic acid spinning solution, adding adriamycin into the spinning solution, and performing ultrasonic dispersion;
step 3, immersing the composite fiber membrane obtained in the step 2 into a dopamine solution to enable dopamine to generate a self-polymerization reaction, so that a poly-dopamine layer is formed on the surface of the polylactic acid-glycolic acid fiber;
and 4, washing and drying the composite fiber membrane prepared in the step 3 to obtain the degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing.
Further, in the step 1, the solvent used by the polylactic acid-glycolic acid spinning solution is a mixed solvent of chloroform and acetone, and the mass ratio of the chloroform to the acetone is 1: 1, the molecular weight of the adopted polylactic acid-glycolic acid is 8-15 ten thousand, the mass fraction of the polylactic acid-glycolic acid in the spinning solution is 10-16%, and the mass fraction of the adriamycin is 5-8%.
Further, in step 2, the electrostatic spinning parameters are as follows: the spinning voltage is 15-25kV, the receiving distance is 20-30cm, the spinning advancing speed is 0.5-1.8mL/h, the ambient temperature is 18-30 ℃, and the humidity is 30% -60%.
Further, in step 3, the concentration of dopamine in the dopamine solution is 1-3mmol/L, the solvent is Tris-HCl buffer solution, and the self-polymerization reaction conditions are as follows: irradiating with light to contact with air at 25-30 deg.C, pH of 7.1-8.0, and polymerizing for 2-5 hr.
Further, in the step 4, deionized water is adopted to wash the composite fiber membrane, and the drying condition is natural drying for 12-24 h.
Has the advantages that:
1. the invention utilizes dopamine autopolymerization reaction to form the PDA photothermal layer on the surface of the PLGA, which not only can endow the fiber dressing with the photothermal anti-tumor function, but also the PDA can enhance the hydrophilicity of the PLGA and is beneficial to the slow release of chemotherapeutic drugs.
2. The materials used in the invention are all biocompatible and degradable materials, which can not cause immunological rejection of human body, and the fiber dressing is made of organic matters, has good flexibility and is easy to be used by being attached to wounds.
3. The degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing provided by the invention has the photothermal and chemotherapeutic dual anti-tumor effects, can thoroughly kill tumor cells of a wound after tumor resection in a large area and a long-term effect, can be used for developing a novel anti-tumor dressing, and is applied to clinical treatment.
Drawings
FIG. 1 is a schematic structural diagram and a schematic cross-sectional diagram of a single fiber of the degradable photothermal chemotherapy synergistic anti-tumor fiber dressing of the invention; wherein: PDA is 1, PLGA is 2, and DOX is 3.
Detailed Description
As shown in figure 1, the invention firstly utilizes the electrostatic spinning technology to prepare the polylactic acid-glycolic acid (PLGA) fibrous membrane containing the antitumor drug Doxorubicin (DOX); then the prepared composite fiber membrane is immersed in a solution containing Dopamine (DA), and a Polydopamine (PDA) layer with a photothermal effect is formed on the surface of the fiber by utilizing dopamine autopolymerization; and finally, cleaning and drying the prepared DOX @ PLGA @ PDA composite fiber membrane to prepare the degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing.
The invention is described in further detail below with reference to the figures and the specific examples, which should not be construed as limiting the invention. Modifications or substitutions to methods, procedures, or conditions of the invention may be made without departing from the spirit and scope of the invention. The experimental methods and reagents of the formulations not specified in the examples are in accordance with the conventional conditions in the art.
Example 1
A degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing, comprising the following steps:
(1) weighing 5g of PLGA particles with the molecular weight of 8 ten thousand, adding 30mL of chloroform and acetone compound solvent (the mass ratio is 1: 1) to prepare PLGA spinning solution, adding 2.5g of DOX into the prepared PLGA spinning solution, stirring, dissolving and ultrasonically dispersing;
(2) performing electrostatic spinning on the mixed spinning solution obtained in the step (1), wherein the spinning voltage is 20kV, the receiving distance is 25cm, the spinning advancing speed is 0.8mL/h, the ambient temperature is 25 ℃, and the humidity is 50%, so as to prepare the PLGA composite fiber membrane doped with the DOX medicament;
(3) immersing the composite fiber membrane in the step (2) into 1mmol/L DA solution for self-polymerization reaction, wherein the solvent is Tris-HCl buffer solution, and the self-polymerization reaction conditions are as follows: irradiating the composite fiber membrane with light to contact air, at the temperature of 25 ℃, the pH value of 7.5 and the polymerization time of 3 hours to prepare the composite fiber membrane coated by the PDA layer;
(4) and (3) washing the DOX @ PLGA @ PDA composite fiber membrane prepared in the step (3) with deionized water, and naturally drying for 12 hours to prepare the degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing.
Example 2
A degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing, comprising the following steps:
(1) weighing 10g of PLGA particles with the molecular weight of 10 ten thousand, adding 60mL of chloroform and acetone compound solvent (the mass ratio is 1: 1) to prepare PLGA spinning solution, adding 5g of DOX into the prepared PLGA spinning solution, stirring, dissolving and ultrasonically dispersing;
(2) performing electrostatic spinning on the mixed spinning solution obtained in the step (1), wherein the spinning voltage is 23kV, the receiving distance is 28cm, the spinning advancing speed is 1.2mL/h, the environmental temperature is 28 ℃, and the humidity is 40%, so as to prepare the PLGA composite fiber membrane doped with the DOX medicament;
(3) immersing the composite fiber membrane in the step (2) into 2mmol/L DA solution for self-polymerization reaction, wherein the solvent is Tris-HCl buffer solution, and the self-polymerization reaction conditions are as follows: irradiating and contacting air with light, at the temperature of 28 ℃, the pH value of 7.8 and the polymerization time of 4 hours to prepare the composite fiber membrane coated by the PDA layer;
(4) and (3) washing the DOX @ PLGA @ PDA composite fiber membrane prepared in the step (3) with deionized water, and naturally drying for 18 hours to prepare the degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing.
Example 3
A degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing, comprising the following steps:
(1) weighing 8g of PLGA particles with molecular weight of 12 ten thousand, adding 50mL of chloroform and acetone compound solvent (mass ratio is 1: 1) to prepare PLGA spinning solution, adding 4g of DOX into the prepared PLGA spinning solution, stirring for dissolving, and performing ultrasonic dispersion;
(2) performing electrostatic spinning on the mixed spinning solution obtained in the step (1), wherein the spinning voltage is 18kV, the receiving distance is 20cm, the spinning advancing speed is 1.6mL/h, the ambient temperature is 18 ℃, and the humidity is 60%, so as to prepare the PLGA composite fiber membrane doped with the DOX medicament;
(3) immersing the composite fiber membrane in the step (2) into 1.5mmol/L DA solution for self-polymerization reaction, wherein the solvent is Tris-HCl buffer solution, and the self-polymerization reaction conditions are as follows: irradiating and contacting air with light, at the temperature of 27 ℃, the pH value of 8.0 and the polymerization time of 5 hours to prepare the composite fiber membrane coated by the PDA layer;
(4) and (3) washing the DOX @ PLGA @ PDA composite fiber membrane prepared in the step (3) with deionized water, and naturally drying for 20 hours to prepare the degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing.
Example 4
A degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing, comprising the following steps:
(1) weighing 9g of PLGA particles with the molecular weight of 15 ten thousand, adding 58mL of chloroform and acetone compound solvent (the mass ratio is 1: 1) to prepare PLGA spinning solution, adding 5.2g of DOX into the prepared PLGA spinning solution, stirring, dissolving and ultrasonically dispersing;
(2) performing electrostatic spinning on the mixed spinning solution obtained in the step (1), wherein the spinning voltage is 25kV, the receiving distance is 30cm, the spinning advancing speed is 1.5mL/h, the ambient temperature is 30 ℃, and the humidity is 46%, so as to prepare the PLGA composite fiber membrane doped with the DOX medicament;
(3) immersing the composite fiber membrane in the step (2) into a 3mmol/L DA solution for self-polymerization reaction, wherein the solvent is Tris-HCl buffer solution, and the self-polymerization reaction conditions are as follows: irradiating and contacting air with light, at the temperature of 27 ℃, the pH value of 7.9 and the polymerization time of 2.8 hours to prepare the composite fiber membrane coated by the PDA layer;
(4) and (3) washing the DOX @ PLGA @ PDA composite fiber membrane prepared in the step (3) with deionized water, and naturally drying for 24 hours to prepare the degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing.
Example 5
A degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing, comprising the following steps:
(1) weighing 12g of PLGA particles with the molecular weight of 14 ten thousand, adding 70mL of chloroform and acetone compound solvent (the mass ratio is 1: 1) to prepare PLGA spinning solution, adding 6.3g of DOX into the prepared PLGA spinning solution, stirring, dissolving and ultrasonically dispersing;
(2) performing electrostatic spinning on the mixed spinning solution obtained in the step (1), wherein the spinning voltage is 16kV, the receiving distance is 20cm, the spinning advancing speed is 0.5mL/h, the ambient temperature is 18 ℃, and the humidity is 52%, so as to prepare the PLGA composite fiber membrane doped with the DOX medicament;
(3) immersing the composite fiber membrane in the step (2) into 2.5mmol/L DA solution for self-polymerization reaction, wherein the solvent is Tris-HCl buffer solution, and the self-polymerization reaction conditions are as follows: irradiating and contacting air with light, at the temperature of 30 ℃, the pH value of 7.7 and the polymerization time of 4.2 hours to prepare the composite fiber membrane coated by the PDA layer;
(4) and (3) washing the DOX @ PLGA @ PDA composite fiber membrane prepared in the step (3) with deionized water, and naturally drying for 20 hours to prepare the degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing.
Test example 1
The photo-thermal performance test is carried out on the DOX @ PLGA @ PDA composite fiber dressing, and the test method specifically comprises the following steps:
the DOX @ PLGA @ PDA composite fiber dressing was irradiated with near infrared light of power 2W and wavelength 808nm for 3 minutes, and the temperature of the fiber film was recorded by means of a thermal infrared imager, with the test results shown in Table 1.
TABLE 1
| Example 1 | Example 2 | Example 3 | Example 4 | Example 5 | |
| Temperature of | 57℃ | 61℃ | 56℃ | 63℃ | 59℃ |
As can be seen from Table 1, the temperature of the dressing can reach 56-63 ℃ after the dressing is irradiated by near infrared light for 3 minutes, and the requirement of killing tumor cells by photo-thermal treatment is met.
Test example 2
The DOX @ PLGA @ PDA composite fiber dressing is subjected to drug slow release performance test, and the method specifically comprises the following steps:
the cumulative drug release rates for the first 5 hours and 7 days of the conjugate fiber dressing in pH 7 phosphate buffer were recorded, respectively, and the results are shown in table 2.
TABLE 2
| Time | Example 1 | Example 2 | Example 3 | Example 4 | Example 5 |
| 5 hours | 13％ | 14％ | 17％ | 15％ | 12％ |
| 7 days | 56％ | 58％ | 61％ | 57％ | 62％ |
As can be seen from Table 2, the dressing has a cumulative release rate of 12-17% 5h before the DOX release rate and 56-62% 7 days after the DOX release rate. The early-stage release rate is relatively low, the phenomenon of drug burst release can be avoided, the later-stage release rate is stable and slow, and the long-acting and lasting anti-tumor requirement is met.
Test example 3
Firstly, a mouse breast cancer postoperative model is established, and the DOX @ PLGA @ PDA composite fiber dressing prepared in the embodiment 1-3 is implanted into a tumor resection part to perform a photo-thermal/chemotherapy synergistic anti-tumor test. Meanwhile, the test results are shown in Table 3 by comparing with the blank group and the DOX intravenous injection group.
TABLE 3
| Example 1 | Example 2 | Example 3 | DOX intravenous injection group | Blank group | |
| Recurrence rate of tumor | 27％ | 26％ | 29％ | 82％ | 100％ |
| Tumor metastasis rate | 15％ | 17％ | 16％ | 72％ | 87％ |
As can be seen from Table 3, the DOX @ PLGA @ PDA composite fiber dressing has a good inhibition effect on wound tumor in-situ recurrence and distal metastasis after tumor resection, can avoid high toxic and side effects brought to patients by a traditional treatment mode, and has a high clinical application value.
Claims (5)
1. A degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing is characterized in that: the fiber dressing is prepared by the following method:
step 1, preparing a polylactic acid-glycolic acid spinning solution, adding adriamycin into the spinning solution, and performing ultrasonic dispersion;
step 2, performing electrostatic spinning on the mixed spinning solution obtained in the step 1 to prepare a polylactic acid-glycolic acid composite fiber membrane doped with adriamycin;
step 3, immersing the composite fiber membrane obtained in the step 2 into a dopamine solution to enable dopamine to generate a self-polymerization reaction, so that a poly-dopamine layer is formed on the surface of the polylactic acid-glycolic acid fiber;
and 4, washing and drying the composite fiber membrane prepared in the step 3 to obtain the degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing.
2. The degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing according to claim 1, wherein: in the step 1, the solvent used by the polylactic acid-glycolic acid spinning solution is a mixed solvent of chloroform and acetone, and the mass ratio of the chloroform to the acetone is 1: 1, the molecular weight of the adopted polylactic acid-glycolic acid is 8-15 ten thousand, the mass fraction of the polylactic acid-glycolic acid in the spinning solution is 10-16%, and the mass fraction of the adriamycin is 5-8%.
3. The degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing according to claim 1, wherein: in step 2, the electrostatic spinning parameters are as follows: the spinning voltage is 15-25kV, the receiving distance is 20-30cm, the spinning advancing speed is 0.5-1.8mL/h, the ambient temperature is 18-30 ℃, and the humidity is 30% -60%.
4. The degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing according to claim 1, wherein: in the step 3, the concentration of dopamine in the dopamine solution is 1-3mmol/L, the solvent is Tris-HCl buffer solution, and the self-polymerization reaction conditions are as follows: irradiating with light to contact with air at 25-30 deg.C, pH of 7.1-8.0, and polymerizing for 2-5 hr.
5. The degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing according to claim 1, wherein: and 4, washing the composite fiber membrane by using deionized water, wherein the drying condition is natural drying for 12-24 h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011529855.5A CN112546284A (en) | 2020-12-22 | 2020-12-22 | Degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011529855.5A CN112546284A (en) | 2020-12-22 | 2020-12-22 | Degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112546284A true CN112546284A (en) | 2021-03-26 |
Family
ID=75032140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011529855.5A Pending CN112546284A (en) | 2020-12-22 | 2020-12-22 | Degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112546284A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113101409A (en) * | 2021-04-09 | 2021-07-13 | 中山大学附属第三医院（中山大学肝脏病医院） | Multifunctional compound bracket and preparation method and application thereof |
| CN113332039A (en) * | 2021-05-31 | 2021-09-03 | 西南大学 | Continuous drainage sugarcane sponge dressing |
| CN114344555A (en) * | 2022-01-12 | 2022-04-15 | 西南交通大学 | Multifunctional hemostatic material and preparation method thereof |
| CN114831966A (en) * | 2022-04-08 | 2022-08-02 | 吉林医药学院 | Photothermal conversion nano composite material without toxic and side effects and preparation method and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100093614A1 (en) * | 2006-03-31 | 2010-04-15 | Leendert Johannes Hofland | Novel Composition for Tumor Growth Control |
| CN102688223A (en) * | 2012-06-11 | 2012-09-26 | 东华大学 | Anti-cancer drug-loading nanofiber film and preparation method thereof |
| CN105833272A (en) * | 2016-04-20 | 2016-08-10 | 国家纳米科学中心 | Multifunctional nano-medicinal composition, as well as preparation method and application thereof |
| CN107737119A (en) * | 2017-11-10 | 2018-02-27 | 华侨大学 | A kind of PCL PLGA sustained release preparations and preparation method thereof |
| CN108992445A (en) * | 2018-08-14 | 2018-12-14 | 西南大学 | Two kinds of anti-tumor drug micrometer fibers films of a kind of load and preparation method thereof |
| CN111375060A (en) * | 2020-03-04 | 2020-07-07 | 浙江大学 | Composite fiber with pH and near-infrared light response drug release and preparation method and application thereof |
| CN111803708A (en) * | 2020-06-23 | 2020-10-23 | 华南理工大学 | 3D-printed hydroxyapatite scaffold composite curcumin macromolecule/polydopamine synergistic anticancer coating and preparation method and application thereof |
-
2020
- 2020-12-22 CN CN202011529855.5A patent/CN112546284A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100093614A1 (en) * | 2006-03-31 | 2010-04-15 | Leendert Johannes Hofland | Novel Composition for Tumor Growth Control |
| CN102688223A (en) * | 2012-06-11 | 2012-09-26 | 东华大学 | Anti-cancer drug-loading nanofiber film and preparation method thereof |
| CN105833272A (en) * | 2016-04-20 | 2016-08-10 | 国家纳米科学中心 | Multifunctional nano-medicinal composition, as well as preparation method and application thereof |
| CN107737119A (en) * | 2017-11-10 | 2018-02-27 | 华侨大学 | A kind of PCL PLGA sustained release preparations and preparation method thereof |
| CN108992445A (en) * | 2018-08-14 | 2018-12-14 | 西南大学 | Two kinds of anti-tumor drug micrometer fibers films of a kind of load and preparation method thereof |
| CN111375060A (en) * | 2020-03-04 | 2020-07-07 | 浙江大学 | Composite fiber with pH and near-infrared light response drug release and preparation method and application thereof |
| CN111803708A (en) * | 2020-06-23 | 2020-10-23 | 华南理工大学 | 3D-printed hydroxyapatite scaffold composite curcumin macromolecule/polydopamine synergistic anticancer coating and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 徐志康等: "《中国战略性新兴产业 新材料 高性能分离膜材料》", 31 December 2017 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113101409A (en) * | 2021-04-09 | 2021-07-13 | 中山大学附属第三医院（中山大学肝脏病医院） | Multifunctional compound bracket and preparation method and application thereof |
| CN113332039A (en) * | 2021-05-31 | 2021-09-03 | 西南大学 | Continuous drainage sugarcane sponge dressing |
| CN114344555A (en) * | 2022-01-12 | 2022-04-15 | 西南交通大学 | Multifunctional hemostatic material and preparation method thereof |
| CN114831966A (en) * | 2022-04-08 | 2022-08-02 | 吉林医药学院 | Photothermal conversion nano composite material without toxic and side effects and preparation method and application thereof |
| CN114831966B (en) * | 2022-04-08 | 2024-04-19 | 吉林医药学院 | Photo-thermal conversion nanocomposite without toxic and side effects as well as preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112546284A (en) | Degradable photothermal/chemotherapeutic synergistic anti-tumor fiber dressing | |
| CN110755613A (en) | Preparation and application of light-triggered erythrocyte membrane-coated NO nano bionic donor material | |
| CN110215438B (en) | Preparation method and application of mesoporous silicon nanoparticles carrying anthracyclines and photosensitizers | |
| CN111110914B (en) | Injectable hydrogel for promoting bone regeneration and preparation method thereof | |
| CN104001178A (en) | Polylactic acid-hydroxyacetic acid copolymer nano-drug carrier as well as preparation method and application thereof | |
| CN107982534B (en) | Preparation method of chitosan/copper sulfide nano composite hollow sphere, product thereof and application thereof | |
| CN103432582A (en) | Preparation method for RGD-targeted porphyrin polymer nanomicelle | |
| CN111375060B (en) | Composite fiber with pH and near-infrared light response drug release and preparation method and application thereof | |
| CN103800292A (en) | Preparation method of organic/inorganic hybrid nano fiber drug carrying microsphere | |
| CN102560887A (en) | Silk fibroin nano-fiber film loaded with vitamins A and E and preparation method thereof | |
| CN109796972A (en) | A kind of carbon quantum dot and its preparation method and application of singlet oxygen control release type | |
| CN107019805A (en) | A kind of self-healing hydrogel drug delivery system for loading doxorubicin hydrochloride | |
| CN104587531B (en) | A kind of preparation method of gel stent of repairing articular cartilage damage | |
| CN111135296A (en) | Albumin-bound indocyanine green anti-tumor photo-thermal preparation and preparation method thereof | |
| CN101843578B (en) | Nanofiber membrane carrying anti-tumor photosensitizer and preparation method thereof | |
| CN113197843A (en) | Dopamine-coated cellulose nanocrystal-agarose drug-loaded hydrogel and preparation method thereof | |
| CN104548095A (en) | PLGA/MoS2 composite drug stent material as well as preparation method and application thereof | |
| CN108912349A (en) | Polylactic acid microsphere and preparation method thereof and the application in medicament slow release | |
| CN110368501B (en) | RGD peptide modified boron drug-loading system and preparation and application thereof | |
| CN111603568A (en) | Charge reversal type polypeptide composite nano-drug and preparation method and application thereof | |
| CN114010799A (en) | Photo-thermal synergistic chemotherapy targeted degradable nano-drug carrier and preparation method thereof | |
| CN114522256B (en) | Polyhydroxyalkanoate drug-loaded radiotherapy microsphere and preparation method and application thereof | |
| CN103627745A (en) | Embedding-crosslinking method for preparing nicotinic acid by Gibberella immobilization bioconversion | |
| CN114831966B (en) | Photo-thermal conversion nanocomposite without toxic and side effects as well as preparation method and application thereof | |
| CN101703786B (en) | Natural macromolecular ultrafine fibrous membrane marked with radioactive nuclide and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210326 |